ArticleFrontiers in immunology2025
Integrative bulk and single-cell transcriptome analyses reveal integrated stress response-related biomarkers in periodontitis with experimental validation.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research progress on BTG2 in non‑tumor diseases (Review).International journal of molecular medicine · 2026Review
- Exploring Matrix Stiffness-Related Gene in Periodontitis: A Comprehensive Multidataset Analysis.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to investigate the role of integrated stress response (ISR)-related biomarkers in periodontitis (PD). Methods: Transcriptomic data related to PD were obtained from public databases. A bioinformatics approach combined with machine learning techniques was used to identify ISR-associated molecular markers involved in PD pathogenesis and to validate their expression patterns. Pathway enrichment analyses and immune landscape characterization were performed to elucidate the molecular mechanisms of these markers in PD progression. Single-cell RNA sequencing (scRNA-seq) was employed to resolve cellular heterogeneity and examine the expression patterns of candidate biomarkers. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assays were conducted to validate the expression profiles. Results: BTG2, DERL3, FOS, HSPA13, and YOD1 were identified as potential PD biomarkers. Among them, BTG2, DERL3, FOS, and HSPA13 were co-enriched in the "osteoclast differentiation" pathway. DERL3 showed the strongest positive correlation with plasma cells and the strongest negative correlation with resting dendritic cells (|cor| > 0.3, P < 0.05). scRNA-seq analysis highlighted T cells as the key population. During T cell differentiation, BTG2 expression initially increased, then decreased, followed by a subsequent rise in the mid-to-late stages; DERL3 expression exhibited a transient increase before returning to baseline; and FOS expression increased gradually throughout the process. RT-qPCR results confirmed that the expression levels of BTG2, DERL3, FOS, and HSPA13 were significantly upregulated, while YOD1 expression was downregulated in the PD group (P < 0.05), which was consistent with the database-predicted patterns. Conclusion: This study integrated bulk and single-cell RNA-seq analyses to identify BTG2, DERL3, FOS, HSPA13, and YOD1 as PD biomarkers, with T cells as the central cell type, providing novel diagnostic insights for PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.